Health Catalyst, Inc. (NASDAQ:HCAT) Receives Average Recommendation of “Hold” from Analysts

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been assigned a consensus recommendation of “Hold” from the fourteen ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $4.3182.

Several research firms have recently commented on HCAT. William Blair reissued an “outperform” rating on shares of Health Catalyst in a research note on Tuesday, November 11th. Wells Fargo & Company lowered their price objective on Health Catalyst from $6.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. KeyCorp dropped their price objective on Health Catalyst from $5.00 to $4.00 and set an “overweight” rating for the company in a report on Wednesday, October 8th. UBS Group reaffirmed an “outperform” rating on shares of Health Catalyst in a research note on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Health Catalyst in a research report on Monday, December 29th.

Health Catalyst Trading Down 4.7%

Shares of Health Catalyst stock opened at $2.25 on Friday. Health Catalyst has a 52-week low of $2.02 and a 52-week high of $5.92. The firm has a market capitalization of $159.14 million, a PE ratio of -1.42 and a beta of 1.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.88 and a quick ratio of 1.88. The company’s fifty day moving average price is $2.46 and its two-hundred day moving average price is $2.96.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Monday, November 10th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.01. The business had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $75.05 million. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%. On average, analysts expect that Health Catalyst will post -0.33 EPS for the current year.

Insider Activity at Health Catalyst

In related news, Director Julie Larson-Green sold 47,997 shares of the company’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $2.67, for a total value of $128,151.99. Following the completion of the sale, the director owned 73,573 shares in the company, valued at $196,439.91. This represents a 39.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Benjamin Landry sold 27,425 shares of the firm’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $2.64, for a total transaction of $72,402.00. Following the sale, the general counsel owned 100,000 shares in the company, valued at approximately $264,000. The trade was a 21.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Health Catalyst

Hedge funds have recently made changes to their positions in the business. Focus Partners Wealth bought a new stake in shares of Health Catalyst in the first quarter worth $46,000. Cresset Asset Management LLC bought a new position in Health Catalyst in the second quarter valued at $39,000. Divergent Planning LLC acquired a new stake in Health Catalyst in the 2nd quarter valued at $45,000. Pilgrim Partners Asia Pte Ltd bought a new stake in Health Catalyst during the 3rd quarter worth about $39,000. Finally, FNY Investment Advisers LLC acquired a new position in shares of Health Catalyst during the 3rd quarter worth about $45,000. 85.00% of the stock is owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.